PMID- 36465365
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221206
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced 
      gallbladder cancer in a second-line setting: A retrospective analysis of a case 
      series.
PG  - 1006075
LID - 10.3389/fonc.2022.1006075 [doi]
LID - 1006075
AB  - BACKGROUND: Gallbladder cancer (GBC) is a fatal cancer, and the efficacy of the 
      current standard second-line chemotherapy for GBC is limited. Novel therapies 
      need to be explored. This retrospective analysis was aimed to investigate the 
      outcomes of patients treated at West China Hospital with PD-1 inhibitors combined 
      with nab-paclitaxel-based chemotherapy (nab-paclitaxel monotherapy or 
      nab-paclitaxel plus other cytotoxic agents) in a second-line setting. METHODS: 
      Between April 2020 and May 2022, the patients with advanced GBC receiving PD-1 
      inhibitors combined with nab-paclitaxel-based chemotherapy after resistance to 
      first-line gemcitabine-based chemotherapy at West China Hospital were 
      retrospectively screened. RESULTS: Eleven patients were included, and all 
      received gemcitabine-based chemotherapy as first-line therapy. Eight patients 
      underwent next-generation sequencing (NGS), and all had microsatellite stability 
      (MSS) and a low tumor mutation burden (TMB). Six patients were negative for PD-L1 
      expression and one patient was positive for PD-L1. Therapeutically relevant 
      genetic alterations were not found. All patients received PD-1 inhibitors in 
      combination with nab-paclitaxel-based chemotherapy as second-line therapy. 
      Pembrolizumab was administered in 3 patients, and sintilimab was administered in 
      eight patients. One patient had no measurable target lesion. Complete response 
      (CR) was observed in one (10.0%) patient, partial response (PR) in four (40%) 
      patients, and stable disease (SD) in four (40%) patients. The median 
      progression-free survival (PFS) was 7.5 (95% CI: 2.5-12.5) months, and the median 
      overall survival (OS) was 12.7 (95% CI: 5.5-19.9) months. The adverse events 
      (AEs) were manageable. CONCLUSION: Our results suggest that PD-1 inhibitors 
      combined with nab-paclitaxel-based chemotherapy as second-line therapy for 
      advanced GBC might be a potential treatment and deserves further evaluation.
CI  - Copyright (c) 2022 Tan, Yu, Huang, Zhou and Gou.
FAU - Tan, Sirui
AU  - Tan S
AD  - Department of Abdominal Cancer, West China Medical School, Cancer Center, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Yu, Jing
AU  - Yu J
AD  - Department of Abdominal Cancer, West China Medical School, Cancer Center, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Huang, Qiyue
AU  - Huang Q
AD  - Department of Abdominal Cancer, West China Medical School, Cancer Center, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Zhou, Nan
AU  - Zhou N
AD  - Department of Abdominal Cancer, West China Medical School, Cancer Center, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Gou, Hongfeng
AU  - Gou H
AD  - Department of Abdominal Cancer, West China Medical School, Cancer Center, West 
      China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20221116
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9709255
OTO - NOTNLM
OT  - PD1
OT  - advanced gallbladder cancer
OT  - chemotherapy
OT  - efficacy
OT  - nab-paclitaxel
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/06 06:01
PMCR- 2022/01/01
CRDT- 2022/12/05 03:40
PHST- 2022/07/28 00:00 [received]
PHST- 2022/10/31 00:00 [accepted]
PHST- 2022/12/05 03:40 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/06 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1006075 [doi]
PST - epublish
SO  - Front Oncol. 2022 Nov 16;12:1006075. doi: 10.3389/fonc.2022.1006075. eCollection 
      2022.